Basic Lab Markers
|
July 24, 2024

Tracking Inflammation Through Biomarkers: What New Tests Can Tell You

Medically Reviewed by
Updated On
September 17, 2024

Inflammation is a fundamental biological response to injury or infection, serving as the body's defense mechanism to promote healing. When this normal physiologic process becomes chronic, inflammation can contribute to the development of diseases, including arthritis, cardiovascular disease, and diabetes.Β 

Understanding inflammation's role in health and disease is crucial for effective diagnosis and treatment. Biomarkers play a pivotal role in this process, providing essential insights into the presence and progression of inflammation, thereby guiding therapeutic decisions and monitoring patient outcomes. This article explores some common biomarkers that reflect levels of inflammation in the body and how they can guide the management and prevention of chronic conditions.Β 

[signup]

Understanding Biomarkers of Inflammation

Biomarkers are indicators of biological states that give objective measures of physiological parameters. These biomarkers can be measured accurately and reproducibly in the blood to reveal clues to a person’s medical state and facilitate medical diagnosis.Β 

Biomarkers that reflect the inflammatory process include C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and interleukins. Evaluating these inflammatory markers gives insights into the presence, severity, and progression of inflammation. These biomarkers help clinicians diagnose inflammatory conditions, monitor the progress of disease, and assess how well treatments are working, thereby playing a vital role in personalized patient care.Β 

The 4 Most Common Biomarkers for Inflammation

Here are the top 4 common biomarkers for inflammation:

1. C-Reactive Protein (CRP)

CRP is produced by the liver and released into the bloodstream in response to inflammation. CRP levels rise quickly in acute inflammatory states, making it a reliable marker for detecting and monitoring inflammation.Β 

2. Erythrocyte Sedimentation Rate (ESR)

The ESR measures the rate at which red blood cells settle at the bottom of a test tube over an hour. Inflammatory processes often cause red blood cells to clump together, become heavier, and settle faster, so a higher ESR indicates higher levels of inflammation.

3. Procalcitonin (PCT)

PCT is a biomarker that is typically elevated when inflammation is present due to bacterial infections and resulting sepsis. It can help distinguish bacterial infections from other causes of inflammation, guiding appropriate treatment strategies.

4. Ferritin

Ferritin is a protein that helps store iron in cells, preventing it from causing harmful reactions in the body. While primarily an indicator of iron storage, elevated ferritin levels can also signal inflammation, as the body often increases ferritin production in response to inflammatory conditions.

Novel Biomarkers and Their Emerging Roles

As understanding inflammation advances, novel biomarkers are emerging, providing deeper insights and enhanced precision in diagnosing and monitoring inflammatory conditions.Β 

Calprotectin

Calprotectin is found in neutrophils and is particularly useful in diagnosing and monitoring inflammatory bowel diseases like Crohn's disease and ulcerative colitis. Its levels in feces can reflect the degree of intestinal inflammation.

Serum Amyloid A (SAA)

SAA responds more rapidly to inflammation than CRP, making it an early indication of inflammatory activity. It is a valuable biomarker for monitoring chronic inflammatory conditions and managing disease.

High-sensitivity CRP (hs-CRP)

hs-CRP (high sensitivity-CRP) is more sensitive for measuring low levels of CRP and detecting minor elevations in CRP associated with chronic, low-grade inflammation. hs-CRP is mainly used in cardiovascular risk assessment.

Soluble Urokinase Plasminogen Activator Receptor (suPAR)

suPAR is a newer biomarker reflecting the level of immune activation. It has been linked to chronic inflammation and disease progression, offering potential insights into conditions like cancer, cardiovascular disease, kidney disease, and infections.

Advanced Testing Technologies

Recent advancements in testing technologies have significantly enhanced the ability to diagnose and monitor inflammation more efficiently and accurately.Β 

Multiplex Assays

Multiplex assays provide a comprehensive overview of a patient's inflammatory status by looking at multiple relevant biomarkers in one evaluation. This multi-analyte approach enhances diagnostic precision and aids in the understanding of complex inflammatory processes.

Point-of-Care Tests

Recent developments in rapid testing technologies allow for measuring biomarkers like CRP, PCT, and erythrocyte aggregation kinetics (EAK) in clinical and home settings. These point-of-care tests offer quick results, facilitating timely decision-making and improving patient care by enabling immediate intervention and monitoring.

Interpreting Biomarker Levels

Accurate interpretation of biomarker levels allows for distinguishing between different types of inflammation and understanding the clinical implications.Β 

Systemic inflammation may reflect infection and noninfectious causes, such as pancreatitis, cardiac ischemia, bowel perforation, vasculitis, and pulmonary embolism. Biomarkers such as CRP and PCT help to differentiate when systemic inflammation is caused by infectious sources.

‍Acute inflammation is often reflected by elevated levels of biomarkers like CRP and SAA, signaling an immediate response to infection or injury.Β 

In contrast, persistently high levels of biomarkers such as ESR and hs-CRP often point to chronic inflammation associated with ongoing conditions like autoimmune diseases and chronic infections.

Monitoring biomarker levels over time can provide insights into disease progression and treatment response. For instance, a decrease in biomarker levels after treatment can suggest effective therapeutic intervention, while an increase might indicate worsening of the disease or an inadequate response to therapy. Thus, monitoring these levels helps healthcare providers make informed decisions about patient management and treatment adjustments.

Biomarkers in Specific Conditions

Biomarkers aid in diagnosis, prognosis, and treatment decisions for many medical conditions.Β 

Autoimmune Diseases

In autoimmune diseases, such as rheumatoid arthritis, lupus, and other conditions that cause joint and back pain, specific biomarkers such as anti-cyclic citrullinated peptide (anti-CCP) antibodies and anti-double-stranded DNA (anti-dsDNA) antibodies serve as diagnostic and prognostic indicators, helping clinicians monitor disease activity and tailor treatment strategies.

Infectious Diseases

Biomarkers like procalcitonin are valuable tools for distinguishing the cause of infections and guiding antibiotic therapy. PCT levels tend to rise more significantly in bacterial infections than viral ones. This distinction is particularly useful in guiding antibiotic therapy, as unnecessary antibiotic use contributes to antimicrobial resistance.

Other inflammatory biomarkers, such as interleukins (e.g., IL-6), tumor necrosis factor-alpha (TNF-alpha), and white blood cell count (WBC), can also provide valuable information about the type and severity of inflammation that can occur in infectious conditions. For example, elevated levels of IL-6 and TNF-alpha are associated with systemic inflammation, seen in conditions like sepsis.

Cardiovascular Diseases

Biomarkers like hs-CRP are utilized for risk assessment and management of cardiovascular diseases, such as heart attack and stroke. Elevated hs-CRP levels indicate inflammation associated with atherosclerosis and increased cardiovascular risk, prompting early intervention and comprehensive individualized approaches to reduce the risk of future adverse cardiac events.

Challenges and Limitations

While these biomarkers provide valuable information to guide clinical management, challenges and limitations exist in using biomarkers in clinical practice.Β 

  • High costs of some biomarker testing can make frequent and repeated testing financially challenging, as advanced tests are often not fully covered by insurance.Β 
  • Accessibility to testing can also be an issue, especially in rural or underserved areas where advanced testing facilities may be unavailable.Β 
  • Additionally, the turnaround time for receiving test results can delay timely medical decisions, further hindering effective health management.​ 

Biomarker levels can vary due to non-inflammatory factors such as age, sex, and comorbid conditions. This variability may complicate interpretation and limit the accuracy of biomarker testing, requiring careful consideration of individual patient characteristics.

Some biomarkers lack specificity, meaning they can be elevated in various conditions other than the target disease. This non-specificity can lead to misinterpretation and overdiagnosis if not considered alongside clinical context and other diagnostic tests.

Future Directions

Future directions in biomarker research hold promising advancements.

Advances in genomic and proteomic technologies offer opportunities to discover new biomarkers with enhanced specificity and sensitivity. Analyzing genetic variations and protein expression patterns associated with inflammation can identify novel biomarkers that can guide the development of treatment strategies based on a deeper understanding of disease mechanisms.

Integrating biomarker testing with other diagnostic modalities, such as imaging and clinical assessments, enables a more comprehensive evaluation of inflammation and its underlying causes. Combining multiple sources of information allows clinicians to tailor treatment strategies based on a patient's individual characteristics and disease profile, leading to more personalized and effective management of inflammation-related conditions.

By leveraging these advancements, future biomarker research aims to improve disease diagnosis, prognosis, and treatment outcomes, ultimately enhancing patient care and contributing to developing precision medicine approaches in healthcare.

[signup]

Key Takeaways

  • Inflammation, essential for healing, can become chronic, contributing to diseases like arthritis and cardiovascular conditions.
  • Biomarkers, including CRP, ESR, and interleukins, are crucial in tracking inflammation, aiding in diagnosis, prognosis, and treatment decisions across various medical conditions.
  • Common biomarkers like CRP and ESR reflect acute inflammation, while novel ones like calprotectin and suPAR offer deeper insights into specific conditions.
  • Advanced testing technologies, such as multiplex assays and point-of-care tests, enhance diagnostic precision and accessibility.
  • Accurate interpretation of biomarker levels distinguishes between types of inflammation and aids in monitoring disease progression and treatment response.
  • Biomarkers play crucial roles in specific conditions, such as autoimmune, infectious, and cardiovascular diseases, guiding diagnosis, prognosis, and treatment decisions.
  • Challenges include variability in biomarker levels and lack of specificity, necessitating careful interpretation.
  • Continued research and development in biomarker discovery and validation are essential to enhance diagnostic accuracy and treatment outcomes.
  • Integrating biomarker testing with other diagnostic tools offers a more holistic approach to managing inflammation, leading to more personalized and effective patient care.
  • The ongoing advancement in genomic, proteomic, and integrative diagnostics holds promise for further improving our understanding of inflammation and its underlying mechanisms, ultimately benefiting patient outcomes and healthcare practices.

Inflammation is a fundamental biological response to injury or infection, serving as the body's defense mechanism to promote healing. When this normal physiologic process becomes chronic, inflammation may contribute to the development of conditions such as arthritis, cardiovascular disease, and diabetes.Β 

Understanding inflammation's role in health and disease is crucial for effective diagnosis and management. Biomarkers play a pivotal role in this process, providing essential insights into the presence and progression of inflammation, thereby guiding therapeutic decisions and monitoring patient outcomes. This article explores some common biomarkers that reflect levels of inflammation in the body and how they can guide the management and support of chronic conditions.Β 

[signup]

Understanding Biomarkers of Inflammation

Biomarkers are indicators of biological states that give objective measures of physiological parameters. These biomarkers can be measured accurately and reproducibly in the blood to reveal clues to a person’s medical state and facilitate medical evaluation.Β 

Biomarkers that reflect the inflammatory process include C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and interleukins. Evaluating these inflammatory markers gives insights into the presence, severity, and progression of inflammation. These biomarkers help clinicians assess inflammatory conditions, monitor the progress of disease, and evaluate how well interventions are working, thereby playing a vital role in personalized patient care.Β 

The 4 Most Common Biomarkers for Inflammation

Here are the top 4 common biomarkers for inflammation:

1. C-Reactive Protein (CRP)

CRP is produced by the liver and released into the bloodstream in response to inflammation. CRP levels rise quickly in acute inflammatory states, making it a reliable marker for detecting and monitoring inflammation.Β 

2. Erythrocyte Sedimentation Rate (ESR)

The ESR measures the rate at which red blood cells settle at the bottom of a test tube over an hour. Inflammatory processes often cause red blood cells to clump together, become heavier, and settle faster, so a higher ESR indicates higher levels of inflammation.

3. Procalcitonin (PCT)

PCT is a biomarker that is typically elevated when inflammation is present due to bacterial infections and resulting sepsis. It can help distinguish bacterial infections from other causes of inflammation, guiding appropriate management strategies.

4. Ferritin

Ferritin is a protein that helps store iron in cells, preventing it from causing harmful reactions in the body. While primarily an indicator of iron storage, elevated ferritin levels can also signal inflammation, as the body often increases ferritin production in response to inflammatory conditions.

Novel Biomarkers and Their Emerging Roles

As understanding inflammation advances, novel biomarkers are emerging, providing deeper insights and enhanced precision in assessing and monitoring inflammatory conditions.Β 

Calprotectin

Calprotectin is found in neutrophils and is particularly useful in assessing and monitoring inflammatory bowel conditions like Crohn's disease and ulcerative colitis. Its levels in feces can reflect the degree of intestinal inflammation.

Serum Amyloid A (SAA)

SAA responds more rapidly to inflammation than CRP, making it an early indication of inflammatory activity. It is a valuable biomarker for monitoring chronic inflammatory conditions and managing disease.

High-sensitivity CRP (hs-CRP)

hs-CRP (high sensitivity-CRP) is more sensitive for measuring low levels of CRP and detecting minor elevations in CRP associated with chronic, low-grade inflammation. hs-CRP is mainly used in cardiovascular risk assessment.

Soluble Urokinase Plasminogen Activator Receptor (suPAR)

suPAR is a newer biomarker reflecting the level of immune activation. It has been linked to chronic inflammation and disease progression, offering potential insights into conditions like cancer, cardiovascular disease, kidney disease, and infections.

Advanced Testing Technologies

Recent advancements in testing technologies have significantly enhanced the ability to assess and monitor inflammation more efficiently and accurately.Β 

Multiplex Assays

Multiplex assays provide a comprehensive overview of a patient's inflammatory status by looking at multiple relevant biomarkers in one evaluation. This multi-analyte approach enhances diagnostic precision and aids in the understanding of complex inflammatory processes.

Point-of-Care Tests

Recent developments in rapid testing technologies allow for measuring biomarkers like CRP, PCT, and erythrocyte aggregation kinetics (EAK) in clinical and home settings. These point-of-care tests offer quick results, facilitating timely decision-making and improving patient care by enabling immediate intervention and monitoring.

Interpreting Biomarker Levels

Accurate interpretation of biomarker levels allows for distinguishing between different types of inflammation and understanding the clinical implications.Β 

Systemic inflammation may reflect infection and noninfectious causes, such as pancreatitis, cardiac ischemia, bowel perforation, vasculitis, and pulmonary embolism. Biomarkers such as CRP and PCT help to differentiate when systemic inflammation is caused by infectious sources.

‍Acute inflammation is often reflected by elevated levels of biomarkers like CRP and SAA, signaling an immediate response to infection or injury.Β 

In contrast, persistently high levels of biomarkers such as ESR and hs-CRP often point to chronic inflammation associated with ongoing conditions like autoimmune diseases and chronic infections.

Monitoring biomarker levels over time can provide insights into disease progression and response to interventions. For instance, a decrease in biomarker levels after an intervention can suggest effective management, while an increase might indicate worsening of the condition or an inadequate response. Thus, monitoring these levels helps healthcare providers make informed decisions about patient management and adjustments.

Biomarkers in Specific Conditions

Biomarkers aid in assessment, prognosis, and management decisions for many medical conditions.Β 

Autoimmune Diseases

In autoimmune diseases, such as rheumatoid arthritis, lupus, and other conditions that cause joint and back pain, specific biomarkers such as anti-cyclic citrullinated peptide (anti-CCP) antibodies and anti-double-stranded DNA (anti-dsDNA) antibodies serve as indicators, helping clinicians monitor disease activity and tailor management strategies.

Infectious Diseases

Biomarkers like procalcitonin are valuable tools for distinguishing the cause of infections and guiding antibiotic use. PCT levels tend to rise more significantly in bacterial infections than viral ones. This distinction is particularly useful in guiding antibiotic use, as unnecessary antibiotic use contributes to antimicrobial resistance.

Other inflammatory biomarkers, such as interleukins (e.g., IL-6), tumor necrosis factor-alpha (TNF-alpha), and white blood cell count (WBC), can also provide valuable information about the type and severity of inflammation that can occur in infectious conditions. For example, elevated levels of IL-6 and TNF-alpha are associated with systemic inflammation, seen in conditions like sepsis.

Cardiovascular Diseases

Biomarkers like hs-CRP are utilized for risk assessment and management of cardiovascular conditions, such as heart attack and stroke. Elevated hs-CRP levels indicate inflammation associated with atherosclerosis and increased cardiovascular risk, prompting early intervention and comprehensive individualized approaches to reduce the risk of future adverse cardiac events.

Challenges and Limitations

While these biomarkers provide valuable information to guide clinical management, challenges and limitations exist in using biomarkers in clinical practice.Β 

  • High costs of some biomarker testing can make frequent and repeated testing financially challenging, as advanced tests are often not fully covered by insurance.Β 
  • Accessibility to testing can also be an issue, especially in rural or underserved areas where advanced testing facilities may be unavailable.Β 
  • Additionally, the turnaround time for receiving test results can delay timely medical decisions, further hindering effective health management.​ 

Biomarker levels can vary due to non-inflammatory factors such as age, sex, and comorbid conditions. This variability may complicate interpretation and limit the accuracy of biomarker testing, requiring careful consideration of individual patient characteristics.

Some biomarkers lack specificity, meaning they can be elevated in various conditions other than the target disease. This non-specificity can lead to misinterpretation and overdiagnosis if not considered alongside clinical context and other diagnostic tests.

Future Directions

Future directions in biomarker research hold promising advancements.

Advances in genomic and proteomic technologies offer opportunities to discover new biomarkers with enhanced specificity and sensitivity. Analyzing genetic variations and protein expression patterns associated with inflammation can identify novel biomarkers that can guide the development of management strategies based on a deeper understanding of disease mechanisms.

Integrating biomarker testing with other diagnostic modalities, such as imaging and clinical assessments, enables a more comprehensive evaluation of inflammation and its underlying causes. Combining multiple sources of information allows clinicians to tailor management strategies based on a patient's individual characteristics and disease profile, leading to more personalized and effective management of inflammation-related conditions.

By leveraging these advancements, future biomarker research aims to improve disease assessment, prognosis, and management outcomes, ultimately enhancing patient care and contributing to developing precision medicine approaches in healthcare.

[signup]

Key Takeaways

  • Inflammation, essential for healing, can become chronic, potentially contributing to conditions like arthritis and cardiovascular issues.
  • Biomarkers, including CRP, ESR, and interleukins, are crucial in tracking inflammation, aiding in assessment, prognosis, and management decisions across various medical conditions.
  • Common biomarkers like CRP and ESR reflect acute inflammation, while novel ones like calprotectin and suPAR offer deeper insights into specific conditions.
  • Advanced testing technologies, such as multiplex assays and point-of-care tests, enhance diagnostic precision and accessibility.
  • Accurate interpretation of biomarker levels distinguishes between types of inflammation and aids in monitoring disease progression and response to interventions.
  • Biomarkers play crucial roles in specific conditions, such as autoimmune, infectious, and cardiovascular diseases, guiding assessment, prognosis, and management decisions.
  • Challenges include variability in biomarker levels and lack of specificity, necessitating careful interpretation.
  • Continued research and development in biomarker discovery and validation are essential to enhance diagnostic accuracy and management outcomes.
  • Integrating biomarker testing with other diagnostic tools offers a more holistic approach to managing inflammation, leading to more personalized and effective patient care.
  • The ongoing advancement in genomic, proteomic, and integrative diagnostics holds promise for further improving our understanding of inflammation and its underlying mechanisms, ultimately benefiting patient outcomes and healthcare practices.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!

Admou, B., Eddehbi, F., Elmoumou, L., Elmojadili, S., Salami, A., Oujidi, M., Brahim, I., & Hazime, R. (2022). Anti-double stranded DNA antibodies: A rational diagnostic approach in limited-resource settings. Practical Laboratory Medicine, 31, e00285. https://doi.org/10.1016/j.plabm.2022.e00285

Ain, Q. U., Sarfraz, M., Prasesti, G. K., Dewi, T. I., & Kurniati, N. F. (2021). Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases. Biomolecules, 11(10), 1464. https://doi.org/10.3390/biom11101464

Alharbi, R. A. (2020). Proteomics approach and techniques in identification of reliable biomarkers for diseases. Saudi Journal of Biological Sciences, 27(3), 968–974. https://doi.org/10.1016/j.sjbs.2020.01.020

Ali, T., Kaitha, S., Mahmood, S., Ftaisi, A., Stone, J., & Bronze, M. (2013). Clinical use of anti-TNF therapy and increased risk of infections. Drug, Healthcare and Patient Safety, 5, 79. https://doi.org/10.2147/dhps.s28801

Anderson, S. (2022, May 19). 6 Preventable Risk Factors Associated With Heart Attacks. Rupa Health. https://www.rupahealth.com/post/5-things-to-do-after-a-heart-attack

Ansar, W., & Ghosh, S. (2016). Inflammation and Inflammatory Diseases, Markers, and Mediators: Role of CRP in Some Inflammatory Diseases. Biology of c Reactive Protein in Health and Disease, 67–107. https://doi.org/10.1007/978-81-322-2680-2_4

Banait, T., Wanjari, A., Danade, V., Banait, S., & Jain, J. (2022). Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review. Cureus, 14(10). https://doi.org/10.7759/cureus.30225

Binnie, A., Lage, J., & Dos Santos, C. C. (2020). How can biomarkers be used to differentiate between infection and non-infectious causes of inflammation? Evidence-Based Practice of Critical Care, 319-324.e1. https://doi.org/10.1016/b978-0-323-64068-8.00055-9

Bodaghi, A., Fattahi, N., & Ramazani, A. (2023). Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon, 9(2), e13323. https://doi.org/10.1016/j.heliyon.2023.e13323

Charansonney, O. L., Al-Dandachi, G., Plaisance, P., & Vicaut, E. (2023). Evaluation of a new point-of-care diagnostic test measuring inflammation in emergency settings. Scientific Reports, 13(1), 19551. https://doi.org/10.1038/s41598-023-46347-x

Chaudry, H., Zhou, J., Zhong, Y., Ali, M. M., Mcquire, F., Nagarkatti, P. S., & Nagarkatti, M. (2013). Role of Cytokines as a Double-edged Sword in Sepsis. In Vivo (Athens, Greece), 27(6), 669–684. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378830/#:~:text=Importantly%2C%20plasma%20and%2For%20serum

Cloyd, J. (2022, December 8). 3 Natural Treatments For Inflammatory Bowel Disease. Rupa Health. https://www.rupahealth.com/post/inflammatory-bowel-disease-ibd-treatments-for-flares-and-remission

Cloyd, J. (2023a, March 17). A Functional Medicine Protocol for Crohn’s Disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-crohns-disease

Cloyd, J. (2023b, March 29). An Integrative Medicine Guide to Ulcerative Colitis. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-guide-to-ulcerative-colitis

Cloyd, J. (2023c, May 1). A Functional Medicine Protocol for Coronary Artery Disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-coronary-artery-disease

Cloyd, J. (2023d, June 19). A Functional Medicine Post Stroke Protocol: Testing, Therapeutic Diet, and Integrative Therapy Options. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-post-stroke-protocol-testing-supplements-and-integrative-therapy-options

Cloyd, J. (2023e, August 25). A Root Cause Medicine Protocol For Patients With Rheumatoid Arthritis: Testing, Therapeutic Diet, and Supportive Supplements. Rupa Health. https://www.rupahealth.com/post/a-root-cause-medicine-protocol-for-patients-with-rheumatoid-arthritis-testing-therapeutic-diet-and-supportive-supplements

Cloyd, J. (2023f, October 24). How Do You Interpret Your Ferritin Blood Test Results? Rupa Health. https://www.rupahealth.com/post/how-do-you-interpret-your-ferritin-blood-test-results

Cloyd, J. (2023g, November 13). The Anti-Inflammatory Lifestyle: From Diet to Mindfulness. Rupa Health. https://www.rupahealth.com/post/the-anti-inflammatory-lifestyle-from-diet-to-mindfulness

Cloyd, J. (2023h, December 5). Inflammation and Heart Disease: A Functional Medicine Approach to Prevention and Treatment. Rupa Health. https://www.rupahealth.com/post/inflammation-and-heart-disease-a-functional-medicine-approach-to-prevention-and-treatment

Cloyd, J. (2023i, December 11). How to Interpret Your CRP Blood Test. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-your-crp-blood-test

Cloyd, K. (2023a, October 3). Functional Medicine Protocol for Autoimmune Diseases: Balancing the Immune System. Rupa Health. https://www.rupahealth.com/post/functional-medicine-protocol-for-autoimmune-diseases-balancing-the-immune-system

Cloyd, K. (2023b, October 4). Inflammation and Gut Health: Understanding the Impact on Overall Well-Being. Rupa Health. https://www.rupahealth.com/post/inflammation-and-gut-health-understanding-the-impact-on-overall-well-being

Durkin, T. J., Barua, B., & Savagatrup, S. (2021). Rapid Detection of Sepsis: Recent Advances in Biomarker Sensing Platforms. ACS Omega, 6(47), 31390–31395. https://doi.org/10.1021/acsomega.1c04788

Justiz Vaillant, A. A., & Qurie, A. (2022, August 22). Interleukin. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK499840/

Kato, S., & Honda, K. (2020). Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. Cancers, 12(7), 1965. https://doi.org/10.3390/cancers12071965

Katsanos, A. H., Kyriakidi, K., Karassa, F. B., Politis, D., Skamnelos, A., Christodoulou, D. K., & Katsanos, K. H. (2017). Biomarker Development in Chronic Inflammatory Diseases. Biomarkers for Endometriosis, 41–75. https://doi.org/10.1007/978-3-319-59856-7_3

Kernan, K. F., & Carcillo, J. A. (2017). Hyperferritinemia and inflammation. International Immunology, 29(9), 401–409. https://doi.org/10.1093/intimm/dxx031

Khakham, C. (2023a, March 28). An integrative medicine approach to kidney disease. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-kidney-disease

Khakham, C. (2023b, April 6). Understanding Your Risk of Cardiovascular Disease With Functional Medicine Labs. Rupa Health. https://www.rupahealth.com/post/understanding-your-risk-of-cardiovascular-disease-with-functional-medicine-labs

Khakham, C. (2023c, June 30). Integrative approaches to the treatment of lupus: A comprehensive review. Rupa Health. https://www.rupahealth.com/post/integrative-approaches-to-the-treatment-of-lupus-a-comprehensive-review

Lee, H. (2013). Procalcitonin as a biomarker of infectious diseases. The Korean Journal of Internal Medicine, 28(3), 285. https://doi.org/10.3904/kjim.2013.28.3.285

Louie, A. D., Huntington, K., Carlsen, L., Zhou, L., & El-Deiry, W. S. (2021). Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.747194

Maholy, N. (2023, May 10). A Functional Medicine Immune Support Protocol. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-immune-support-protocol

Malani, S. (2023a, February 22). Inflammatory Markers 101: How To Interpret. Rupa Health. https://www.rupahealth.com/post/inflammatory-markers-101-what-do-they-mean

Malani, S. (2023b, March 8). What is Integrative Oncology and How Can it Help Your Cancer Journey? Rupa Health. https://www.rupahealth.com/post/what-is-integrative-oncology-and-how-can-it-help-your-cancer-journey

Medline Plus. (n.d.). CCP Antibody Test: MedlinePlus Medical Test. Medlineplus.gov. https://medlineplus.gov/lab-tests/ccp-antibody-test/

MedlinePlus. (2022a, September 28). C-Reactive Protein (CRP) Test: MedlinePlus Lab Test Information. Medlineplus.gov. https://medlineplus.gov/lab-tests/c-reactive-protein-crp-test/

MedlinePlus. (2022b, November 8). Erythrocyte Sedimentation Rate (ESR): MedlinePlus Lab Test Information. Medlineplus.gov. https://medlineplus.gov/lab-tests/erythrocyte-sedimentation-rate-esr/

Menzel, A., Samouda, H., Dohet, F., Loap, S., Ellulu, M. S., & Bohn, T. (2021). Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practiceβ€”Which to Use Regarding Disease Outcomes? Antioxidants, 10(3), 414. https://doi.org/10.3390/antiox10030414

Morris, P., Ali, K., Merritt, M., Pelletier, J., & Macedo, L. G. (2020). A systematic review of the role of inflammatory biomarkers in acute, subacute and chronic non-specific low back pain. BMC Musculoskeletal Disorders, 21(1). https://doi.org/10.1186/s12891-020-3154-3

Mugundhan Kandhasami, Subash Panchanathan, Rajendran, J., & Karthik Balajee Laksham. (2023). High Sensitivity C-Reactive Protein as a Prognostic Indicator of Cardiovascular Disease in Severe Non-Diabetic COVID-19 Patients. PubMed, 11(3), e172–e172. https://doi.org/10.15190/d.2023.11

Pathirana, W. G. W., Chubb, S. P., Gillett, M. J., & Vasikaran, S. D. (2018). Faecal Calprotectin. The Clinical Biochemist. Reviews, 39(3), 77–90. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370282/

Preston, J. (2023, September 22). Addressing Inflammation in Chronic Diseases: A Functional Medicine Perspective. Rupa Health. https://www.rupahealth.com/post/addressing-inflammation-in-chronic-diseases-a-functional-medicine-perspective

Preston, J. (2024, February 7). Iron 101: RDA, Iron-Rich Foods, and Supplementation. Rupa Health. https://www.rupahealth.com/post/iron-101-rda-iron-rich-foods-and-supplementation

Puntmann, V. O. (2009). How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgraduate Medical Journal, 85(1008), 538–545. https://doi.org/10.1136/pgmj.2008.073759

Rasmussen, L. J. H., Petersen, J. E. V., & Eugen-Olsen, J. (2021). Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.780641

Restrepo, J. C., DueΓ±as, D., Corredor, Z., & Liscano, Y. (2023). Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment. Cancers, 15(13), 3474–3474. https://doi.org/10.3390/cancers15133474

Samsudin, I., & Vasikaran, S. D. (2017). Clinical Utility and Measurement of Procalcitonin. The Clinical Biochemist Reviews, 38(2), 59–68. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759088/

Sorić Hosman, I., Kos, I., & Lamot, L. (2021). Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.631299

Stanford, J. (2024, March 21). Insulin Resistance and Inflammation: Understanding the Connection. Rupa Health. https://www.rupahealth.com/post/insulin-resistance-and-inflammation-understanding-the-connection

Strimbu, K., & Tavel, J. A. (2010). What are biomarkers? Current Opinion in HIV and AIDS, 5(6), 463–466. https://doi.org/10.1097/coh.0b013e32833ed177

Subbiah, V. (2023). The next generation of evidence-based medicine. Nature Medicine, 29, 1–10. https://doi.org/10.1038/s41591-022-02160-z

Takemura, Y., Ishida, H., & Inoue, Y. (2003). Utilization of Common Inflammatory Markers in New, Symptomatic, Primary Care Outpatients Based on Their Cost-Effectiveness. Clinical Chemistry and Laboratory Medicine, 41(5). https://doi.org/10.1515/cclm.2003.101

Tanaka, T., Narazaki, M., & Kishimoto, T. (2014). IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology, 6(10), a016295–a016295. https://doi.org/10.1101/cshperspect.a016295

Viswanathan, T. (2019, October 12). The Cost of Functional Medicine Lab Testing & Diagnostics. Rupa Health. https://www.rupahealth.com/post/the-cost-of-functional-medicine-lab-testing-diagnostics

Weinberg, J. L. (2023, July 27). Integrative Approaches to the Testing and Treatment of Rheumatoid Arthritis: A Comprehensive Review. Rupa Health. https://www.rupahealth.com/post/integrative-approaches-to-the-testing-and-treatment-of-rheumatoid-arthritis-a-comprehensive-review

Yoshimura, H. (2023a, July 17). Using Functional Medicine As Personalized Medicine. Rupa Health. https://www.rupahealth.com/post/using-functional-medicine-as-personalized-medicine

Yoshimura, H. (2023b, September 20). Decoding High Calprotectin Levels: Causes, Implications, and Effective Treatment Strategies. Rupa Health. https://www.rupahealth.com/post/decoding-high-calprotectin-levels-causes-implications-and-effective-treatment-strategies

Yoshimura, H. (2023c, October 10). A Root Cause Medicine Approach to Chronic Inflammation. Rupa Health. https://www.rupahealth.com/post/a-root-cause-medicine-approach-to-chronic-inflammation

Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless β€” and best of all, it's free for practitioners.

Latest Articles

View more on Basic Lab Markers
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
Visit Source
National Library of Medicine
Government Authority
Visit Source
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
Visit Source
National Cancer Institute
Government Authority
Visit Source
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
Visit Source
CDC
Government Authority
Visit Source
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
Visit Source
National Institutes of Health
Government Authority
Visit Source
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Visit Source
Brain
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Chest
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source
Visit Source

Hey practitioners! πŸ‘‹ Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.

Hey practitioners! πŸ‘‹ Join Dr. Terry Wahls for a 3-week bootcamp on integrating functional medicine into conventional practice, focusing on complex cases like Multiple Sclerosis. Learn to analyze labs through a functional lens, perform nutrition-focused physical exams, and develop personalized care strategies. Register Here.